Avid Bioservices (CDMO) Competitors $12.39 +0.01 (+0.08%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CDMO vs. VCEL, ACAD, XENE, MLTX, MOR, DNLI, SWTX, MRUS, ZLAB, and BHCShould you be buying Avid Bioservices stock or one of its competitors? The main competitors of Avid Bioservices include Vericel (VCEL), ACADIA Pharmaceuticals (ACAD), Xenon Pharmaceuticals (XENE), MoonLake Immunotherapeutics (MLTX), MorphoSys (MOR), Denali Therapeutics (DNLI), SpringWorks Therapeutics (SWTX), Merus (MRUS), Zai Lab (ZLAB), and Bausch Health Companies (BHC). These companies are all part of the "pharmaceutical products" industry. Avid Bioservices vs. Vericel ACADIA Pharmaceuticals Xenon Pharmaceuticals MoonLake Immunotherapeutics MorphoSys Denali Therapeutics SpringWorks Therapeutics Merus Zai Lab Bausch Health Companies Vericel (NASDAQ:VCEL) and Avid Bioservices (NASDAQ:CDMO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, community ranking, valuation, earnings, analyst recommendations, institutional ownership and profitability. Which has more volatility & risk, VCEL or CDMO? Vericel has a beta of 1.72, meaning that its share price is 72% more volatile than the S&P 500. Comparatively, Avid Bioservices has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Do institutionals & insiders have more ownership in VCEL or CDMO? 97.2% of Avid Bioservices shares are owned by institutional investors. 7.2% of Vericel shares are owned by company insiders. Comparatively, 3.1% of Avid Bioservices shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community believe in VCEL or CDMO? Avid Bioservices received 19 more outperform votes than Vericel when rated by MarketBeat users. Likewise, 65.95% of users gave Avid Bioservices an outperform vote while only 61.80% of users gave Vericel an outperform vote. CompanyUnderperformOutperformVericelOutperform Votes35161.80% Underperform Votes21738.20% Avid BioservicesOutperform Votes37065.95% Underperform Votes19134.05% Is VCEL or CDMO more profitable? Vericel has a net margin of 1.56% compared to Avid Bioservices' net margin of -101.07%. Vericel's return on equity of 1.48% beat Avid Bioservices' return on equity.Company Net Margins Return on Equity Return on Assets Vericel1.56% 1.48% 0.96% Avid Bioservices -101.07%-33.18%-8.45% Does the media prefer VCEL or CDMO? In the previous week, Vericel had 18 more articles in the media than Avid Bioservices. MarketBeat recorded 23 mentions for Vericel and 5 mentions for Avid Bioservices. Avid Bioservices' average media sentiment score of 0.48 beat Vericel's score of 0.26 indicating that Avid Bioservices is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 4 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Avid Bioservices 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate VCEL or CDMO? Vericel currently has a consensus target price of $62.14, suggesting a potential upside of 5.20%. Avid Bioservices has a consensus target price of $12.25, suggesting a potential downside of 1.13%. Given Vericel's stronger consensus rating and higher possible upside, equities research analysts plainly believe Vericel is more favorable than Avid Bioservices.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vericel 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Avid Bioservices 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has stronger earnings & valuation, VCEL or CDMO? Vericel has higher revenue and earnings than Avid Bioservices. Avid Bioservices is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVericel$197.52M14.76-$3.18M$0.06984.66Avid Bioservices$139.91M5.66-$140.75M-$2.39-5.18 SummaryVericel beats Avid Bioservices on 14 of the 18 factors compared between the two stocks. Get Avid Bioservices News Delivered to You Automatically Sign up to receive the latest news and ratings for CDMO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDMO vs. The Competition Export to ExcelMetricAvid BioservicesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$792.46M$6.58B$5.36B$9.09BDividend YieldN/A2.95%5.13%4.03%P/E Ratio-5.189.8389.4717.33Price / Sales5.66307.681,253.32134.80Price / Cash80.4661.4443.7535.97Price / Book4.106.055.324.80Net Income-$140.75M$154.62M$122.60M$224.91M7 Day Performance-0.16%-1.70%0.87%1.90%1 Month Performance0.73%2.75%4.80%5.08%1 Year Performance102.78%2.60%27.90%21.15% Avid Bioservices Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDMOAvid Bioservices2.3629 of 5 stars$12.39+0.1%$12.25-1.1%+97.9%$792.46M$139.91M-5.18320VCELVericel1.7626 of 5 stars$59.90+0.7%$61.14+2.1%+56.1%$2.96B$226.84M998.50300Analyst ForecastAnalyst RevisionNews CoverageACADACADIA Pharmaceuticals4.0028 of 5 stars$17.73+2.7%$25.25+42.4%-37.2%$2.95B$929.24M22.73510Short Interest ↑News CoverageXENEXenon Pharmaceuticals2.707 of 5 stars$38.15-0.7%$56.00+46.8%-15.6%$2.91B$9.43M-13.53210News CoveragePositive NewsMLTXMoonLake Immunotherapeutics1.9666 of 5 stars$45.41-2.0%$81.43+79.3%-22.3%$2.90BN/A-35.202Analyst UpgradeNews CoverageGap UpMORMorphoSys0.2136 of 5 stars$18.96flat$14.33-24.4%N/A$2.86B$238.28M-5.45730DNLIDenali Therapeutics4.4114 of 5 stars$19.34+1.3%$38.91+101.2%+28.1%$2.78B$330.53M-7.01430Analyst ForecastShort Interest ↑SWTXSpringWorks Therapeutics1.6334 of 5 stars$37.38-13.1%$70.00+87.3%-13.8%$2.78B$135.49M-9.63230Analyst RevisionNews CoverageMRUSMerus2.9738 of 5 stars$40.46-7.7%$85.64+111.7%+22.7%$2.77B$35.93M-10.2437Short Interest ↓News CoverageHigh Trading VolumeZLABZai Lab2.4769 of 5 stars$25.01-1.1%$55.00+119.9%+11.2%$2.74B$355.75M-9.032,175News CoverageBHCBausch Health Companies3.3235 of 5 stars$7.40-6.1%$7.75+4.7%-8.9%$2.68B$9.47B-15.4220,270Short Interest ↓News CoveragePositive News Related Companies and Tools Related Companies VCEL Alternatives ACAD Alternatives XENE Alternatives MLTX Alternatives MOR Alternatives DNLI Alternatives SWTX Alternatives MRUS Alternatives ZLAB Alternatives BHC Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CDMO) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avid Bioservices, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avid Bioservices With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CDMO Stock Alerts